ArticleTropical medicine and health2026
Clinical evaluation of recombinant antigen ELISAs and broad-range helminth PCRs for the diagnosis of human paragonimiasis in Gabon.
Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundParagonimiasis is a neglected food-borne trematode infection endemic to parts of Africa, Asia, and the Americas acquired by raw/undercooked freshwater crab consumption. Pulmonary manifestations mimic pulmonary tuberculosis (TB). Diagnosis relies on microscopy, with low sensitivity. Development of molecular assays is constrained by an absence of genomic data for African Paragonimus species. Serological testing depends on crude worm antigen, resulting in restricted availability and reproducibility.
methodsThis study was nested within a prospective cohort of adults with presumed TB in Lambaréné, Gabon. The reference standard for paragonimiasis consisted of sputum and stool microscopy. Molecular index tests included PCRs (ITS2, cox1) on sputum and stool, followed by sequencing. Serological index tests consisted of recombinant ELISAs using GST-tagged Myo-1, MDP, and Egg antigens. Diagnostic accuracy was evaluated using positive control sera (three individuals with confirmed P. westermani infection). Stool, urine and blood were examined for potentially serologically cross-reactive parasites.
resultsAmong 103 participants (enrolled September 2024-January 2025), no Paragonimus eggs were detected. PCR assays amplified only non-Paragonimus sequences, including other helminths. Control sera (confirmed P. westermani) showed marked reactivity, particularly toward Myo-1 and Egg antigen, background reactivity in participants was generally low. Without confirmed cases of African paragonimiasis, we could only calculate analytical sensitivity for P. westermani-sera. Exploratory cut-offs resulted in tentative diagnostic sensitivity between 17 and 100%. Exploratory cut-offs yielded specificities of 76-100%, assuming that no infections were missed by the reference standard. No relevant cross-reactivity with other infections was observed.
conclusionsIn this first real-life application of recombinant antigen-based ELISAs for the serodiagnosis of paragonimiasis, our results showed promise, particularly for Myo-1 and Egg antigen. These results require further validation in larger and diverse populations including cases with African Paragonimus species to better define the epidemiology and burden of paragonimiasis in Gabon and beyond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.